The modified suture placement of the tarsal strip reported in this work improves the lower eyelid stability and prevents future recurrences after surgery. This modified technique is useful for the management of patients with entropion and moderate eyelid dysfunction retractors without other surgical procedures.
ABSTRACT.Purpose: To assess the efficacy of sodium hyaluronate as vehicle for diluting autologous serum. Methods: The concentration and temporal stability of EGF, TGF-b, PDGF-AB and albumin in fresh and frozen samples of autologous serum diluted with sodium hyaluronate and saline solution, as well as the pH, osmolarity and density was studied. In parallel, the clinic effects of autologous serum diluted to 20% with sodium hyaluronate were compared with another solution of autologous serum diluted to 20% with saline in a prospective, comparative, randomized and double-blind study in 26 patients (52 eyes) with Sjo¨gren syndrome. Patients underwent a complete ophthalmic assessment including tear film evaluation and corneal and conjunctival impression cytology at the beginning of the study and 2 months later. Results: The growth factor (GF) concentration remained stable during 1 month at 4°C both in fresh and defrosted samples without any differences being found between both preparations. No differences were found related to osmolarity, pH and density between these preparations before and after frosting. Autologous serum diluted with sodium hyaluronate caused a significant improvement of the tear film stability, fluorescein and rose Bengal stain, break-up time, corneal and conjunctival squamous metaplasia as well as in the patient subjective perception. Conclusions: Sodium hyaluronate is an excellent vehicle for diluting autologous serum due to the gradual release of GF and increasing their duration and effect on the ocular surface. Preparations diluted with sodium hyaluronate are better tolerated by patients and require a lower number of drops administrations.
RESUMENObjetivo: Establecer un protocolo razonado para la preparación y manejo de la terapia con suero autó-logo en la práctica oftalmológica. Métodos: Revisión bibliográfica y experiencia personal. Resultados: La utilización de suero autólogo en colirio ha sido referida por muchos autores como una nueva forma de terapia en el manejo de enfermedades de la superficie ocular. El suero autólogo presenta unas propiedades mecánicas y bioquímicas similares a las de la lágrima, y como ésta contiene componentes como la fibronectina, vitamina A y factores de crecimiento que tienen un efecto epiteliotrófico sobre las células epiteliales de la superficie ocular. Conclusiones: Los distintos estudios publicados muestran una importante variabilidad tanto en la eficacia de esta terapia como en la metodología de preparación y aplicación.Palabras clave: Suero autólogo, superficie ocular, ojo seco, epitelio corneal, citología de impresión.
REVISIÓN ABSTRACTObjective: To establish a protocol for the use of autologous serum in the ophthalmic practice. Methods: Personal experience and a literature review. Results: The use of autologous serum, in eye drop form, has been reported as a new treatment for several ocular surfaces diseases. These products have biomechanical and biochemical properties similar to normal tears. They contain components such as fibronectin, vitamin A and growth factors that have an epitheliotrophic effect on the ocular surface epithelial cells.
Conclusions:The clinical studies performed showed a variable efficacy, with the preparative process and use of the autologous serum eye drops varying considerably between different studies (Arch Soc Esp Oftalmol 2007; 82: 9-20).
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.